Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00692640 · ClinicalTrials.gov registry record · Phase 1
Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00692640 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 35 participants.
The verdict
NCT00692640, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of XL147 in combination with erlotinib (Tarceva®) in subjects with solid tumors. XL147 is a new chemical entity that inhibits PI3 Kinase. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells. Erlotinib is an orally administered inhibitor of EGFR (also known as HER1) tyrosine kinase. It was approved by the FDA as a single agent for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen and in combination with gemcitabine for first line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Interventions
- DRUG Erlotinib
- DRUG XL147 (SAR245408)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00692640
The ClinicalTrials.gov registry entry for NCT00692640 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT00692640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00692640 about?
NCT00692640 is a clinical study titled "Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors". The purpose of this study is to evaluate the safety and tolerability of XL147 in combination with erlotinib (Tarceva®) in subjects with solid tumors. XL147 is a new chemical entity that inhibits PI3 Kinase. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell d...
What is the current status of trial NCT00692640?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2008-05. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00692640?
The interventions under investigation include: Erlotinib (DRUG), XL147 (SAR245408) (DRUG).
Who is sponsoring clinical trial NCT00692640?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.